Palivizumab in preemies reduces wheezing, study finds

05/8/2013 | DoctorsLounge.com

Premature babies who were given monoclonal antibody palivizumab to protect against respiratory syncytial virus infection had 61% fewer days of wheezing in the first year of life than the placebo group, Dutch researchers found. They also noted a lower number of infants with recurrent wheeze in the palivizumab group. The study was published in the New England Journal of Medicine.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA